Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Aug 12, 2022
Date Accepted: Jan 31, 2023
Communicating health literacy about prescription medications on social media: In-depth interviews with “patient influencers”
ABSTRACT
Background:
It is commonplace for social media influencers to work in paid partnerships with brands; this is a multi-billion dollar industry. Long have patients been active in online health communities and social media platforms like Twitter and Instagram, but in recent years pharmaceutical marketers have noticed the power of patient persuasion.
Objective:
The current study explored how patient influencers communicate health literacy about pharmaceutical medications on social media to their communities of followers.
Methods:
Twenty-six in-depth interviews revealed how patient influencers communicate health literacy about pharmaceutical medications to other patients on social media.
Results:
Using the constructs of the Health Belief Model (HBM) to guide the analysis, three themes were identified: understanding disease through experience, staying informed of science/field, and suggesting that physicians know best.
Conclusions:
Just like with traditional direct-to-consumer (DTC) advertising, the phenomenon of patient influencers raises ethical questions that need more investigation. In a way, patient influencers are interactive health education agents who may also share prescription medication information. They can break down complex health information based on expertise and experience and mitigate the loneliness and isolation that other patients may feel without the support of a community.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.